RU2298012C2 - Улучшенные хелатные конъюгаты - Google Patents

Улучшенные хелатные конъюгаты Download PDF

Info

Publication number
RU2298012C2
RU2298012C2 RU2003137592/04A RU2003137592A RU2298012C2 RU 2298012 C2 RU2298012 C2 RU 2298012C2 RU 2003137592/04 A RU2003137592/04 A RU 2003137592/04A RU 2003137592 A RU2003137592 A RU 2003137592A RU 2298012 C2 RU2298012 C2 RU 2298012C2
Authority
RU
Russia
Prior art keywords
compound
group
mmol
acid
radioactive
Prior art date
Application number
RU2003137592/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2003137592A (ru
Inventor
Колин Милл АРЧЕР (GB)
Колин Милл АРЧЕР
Гарри Джон УОДСВОРТ (GB)
Гарри Джон УОДСВОРТ
Торгрим ЭНГЕЛЛ (NO)
Торгрим ЭНГЕЛЛ
Original Assignee
Джи-И Хелткер Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джи-И Хелткер Лимитед filed Critical Джи-И Хелткер Лимитед
Publication of RU2003137592A publication Critical patent/RU2003137592A/ru
Application granted granted Critical
Publication of RU2298012C2 publication Critical patent/RU2298012C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/36—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
RU2003137592/04A 2001-07-10 2002-07-10 Улучшенные хелатные конъюгаты RU2298012C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0116815.2A GB0116815D0 (en) 2001-07-10 2001-07-10 Improved chelator conjugates
GB0116815.2 2001-07-10

Publications (2)

Publication Number Publication Date
RU2003137592A RU2003137592A (ru) 2005-05-20
RU2298012C2 true RU2298012C2 (ru) 2007-04-27

Family

ID=9918227

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003137592/04A RU2298012C2 (ru) 2001-07-10 2002-07-10 Улучшенные хелатные конъюгаты

Country Status (20)

Country Link
US (2) US7597875B2 (enExample)
EP (1) EP1404377B1 (enExample)
JP (1) JP5015409B2 (enExample)
KR (1) KR100892009B1 (enExample)
CN (4) CN101537190A (enExample)
AT (1) ATE304866T1 (enExample)
AU (1) AU2002317317B2 (enExample)
BR (1) BR0210965A (enExample)
CA (1) CA2450690C (enExample)
DE (1) DE60206272T2 (enExample)
DK (1) DK1404377T3 (enExample)
ES (1) ES2250671T3 (enExample)
GB (1) GB0116815D0 (enExample)
HU (1) HU228850B1 (enExample)
IL (1) IL159388A0 (enExample)
MX (1) MXPA04000210A (enExample)
NO (1) NO334093B1 (enExample)
RU (1) RU2298012C2 (enExample)
WO (1) WO2003006070A2 (enExample)
ZA (1) ZA200400143B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2433657A1 (en) * 2001-01-05 2002-07-11 Duke University Contrast enhancement agent for magnetic resonance imaging
CN1622830A (zh) * 2001-07-10 2005-06-01 安盛药业有限公司 肽基化合物
NO20030115D0 (no) 2003-01-09 2003-01-09 Amersham Health As Kontrastmiddel
US7785566B2 (en) 2003-11-06 2010-08-31 Ge Healthcare, Inc. Pharmaceutical compounds
GB0416062D0 (en) 2004-07-19 2004-08-18 Amersham Plc Improved N4 chelator conjugates
US7431914B2 (en) 2003-11-24 2008-10-07 Ge Healthcare As Contrast agent
CN1925876A (zh) * 2004-03-04 2007-03-07 通用电气医疗集团股份有限公司 用于诊断和治疗的血管紧张素肽类似物和螯合剂的缀合物
AU2005307195A1 (en) * 2004-11-22 2006-05-26 Ge Healthcare As Contrast agents to target extracellular matrix
GB0427392D0 (en) * 2004-12-15 2005-01-19 Amersham Plc Stabilised 99mTc compositions
US20080226555A1 (en) * 2005-06-08 2008-09-18 Bengt Langstrom Method for the Use of [11C] Carbon Monoxide in Labeling Synthesis of 11C-Labelled Esters and Acids by Sensitized Photo-Induced Free Radical
GB0515974D0 (en) * 2005-08-03 2005-09-07 Ge Healthcare Ltd Compounds and imaging methods
DE602007012208D1 (de) 2006-02-15 2011-03-10 Ge Healthcare As Kontrastmittel
US7943117B2 (en) * 2006-06-08 2011-05-17 Atomic Energy Council—Institute of Nuclear Research Method for testing radiochemical purity of Tc-99m-TRODAT-1
WO2008072973A2 (en) * 2006-12-11 2008-06-19 Ge Healthcare As Radiolabelled peptide based compounds and uses thereof
ES2712881T3 (es) 2008-12-02 2019-05-16 Univ Melbourne Conjugados macrocíclicos que contienen nitrógeno como radiofármacos
GB0922014D0 (en) 2009-12-17 2010-02-03 Ge Healthcare Ltd Novel integrin binders
ES2804509T3 (es) 2010-07-27 2021-02-08 Serac Healthcare Ltd Composiciones radiofarmacéuticas
GB201103696D0 (en) 2011-03-04 2011-04-20 Ge Healthcare Ltd Technetium labelled peptides
GB201110767D0 (en) 2011-06-24 2011-08-10 Ge Healthcare Ltd Infection imaging
US20130195756A1 (en) 2012-01-31 2013-08-01 General Electric Company 99mTc IMAGING AGENTS AND METHODS OF USE
CA2901231C (en) * 2013-02-15 2020-06-23 Thomas Jefferson University Kit comprising lyophilized compositions for tumor imaging
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
US11033642B2 (en) 2014-03-19 2021-06-15 Universitat Zurich Multidentate bifunctional chelating agents for radionuclide complexation in diagnostics and therapy
CN112840025A (zh) * 2018-05-08 2021-05-25 迈阿密大学 用于将治疗性核酸递送到组织的材料方法
CN112105393A (zh) 2018-05-16 2020-12-18 爱默蕾大学 苯乙烯基苯并噻唑衍生物及在成像中的用途
CN111548275A (zh) * 2020-05-27 2020-08-18 龙曦宁（上海）医药科技有限公司 一种2-（氨基甲基）-n1,n1-二甲基丙烷-1,3-二胺三盐酸盐的合成方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU97118152A (ru) * 1995-03-31 1999-08-10 Диатайд, Инк. Меченые радиоактивным изотопом пептиды для диагностики и терапии
WO1999060018A1 (en) * 1998-05-15 1999-11-25 Nycomed Amersham Plc Labelled glutamine and lysine analogues
US5997843A (en) * 1993-08-04 1999-12-07 Amersham International Plc Radiometal complexes that localise in hypoxic tissue

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1588978A (en) * 1977-07-19 1981-05-07 Ici Ltd Coating processes
DE3930674A1 (de) * 1989-09-11 1991-03-21 Diagnostikforschung Inst Bifunktionelle chelatbildner zur komplexierung von tc- und re-isotopen, verfahren zu ihrer herstellung und darstellung von konjugaten daraus sowie deren verwendung in diagnostik und therapie
US5849261A (en) * 1991-02-08 1998-12-15 Diatide, Inc. Radiolabeled vasoactive intestinal peptides for diagnosis and therapy
US5808091A (en) * 1991-10-29 1998-09-15 Bracco International B.V. Rhenium and technetium complexes containing a hypoxia localizing moiety
CA2156605A1 (en) * 1994-01-12 1995-07-20 Bracco International B.V. Ligands and metal complexes thereof
CA2179990A1 (en) * 1994-01-12 1995-07-20 Gary Robert Bower Biological targeting agents
US6783711B2 (en) * 2000-05-23 2004-08-31 Ge Osmonics, Inc. Process for preparing a sulfonamide polymer matrix
US6988794B2 (en) * 2001-03-08 2006-01-24 Matsushita Electric Industrial Co., Ltd. Inkjet recording ink, method for producing said ink, and ink cartridge and recording device having said ink

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997843A (en) * 1993-08-04 1999-12-07 Amersham International Plc Radiometal complexes that localise in hypoxic tissue
RU97118152A (ru) * 1995-03-31 1999-08-10 Диатайд, Инк. Меченые радиоактивным изотопом пептиды для диагностики и терапии
WO1999060018A1 (en) * 1998-05-15 1999-11-25 Nycomed Amersham Plc Labelled glutamine and lysine analogues

Also Published As

Publication number Publication date
DE60206272T2 (de) 2006-07-13
HUP0401265A2 (hu) 2004-09-28
RU2003137592A (ru) 2005-05-20
WO2003006070A2 (en) 2003-01-23
US20040258619A1 (en) 2004-12-23
US8852550B2 (en) 2014-10-07
KR20040017287A (ko) 2004-02-26
US20100040542A1 (en) 2010-02-18
CN101537190A (zh) 2009-09-23
HU228850B1 (en) 2013-06-28
DE60206272D1 (de) 2005-10-27
CN1527727A (zh) 2004-09-08
US7597875B2 (en) 2009-10-06
JP2005500325A (ja) 2005-01-06
IL159388A0 (en) 2004-06-01
BR0210965A (pt) 2004-06-08
CN101607913A (zh) 2009-12-23
HUP0401265A3 (en) 2005-11-28
JP5015409B2 (ja) 2012-08-29
HK1064585A1 (en) 2005-02-04
WO2003006070A3 (en) 2003-08-21
CA2450690A1 (en) 2003-01-23
CN100509061C (zh) 2009-07-08
KR100892009B1 (ko) 2009-04-07
AU2002317317B2 (en) 2005-11-17
CA2450690C (en) 2009-03-24
EP1404377B1 (en) 2005-09-21
EP1404377A2 (en) 2004-04-07
NO20035597L (no) 2004-03-03
ZA200400143B (en) 2004-12-29
DK1404377T3 (da) 2006-01-30
NO334093B1 (no) 2013-12-09
NO20035597D0 (no) 2003-12-16
CN101538313A (zh) 2009-09-23
CN101607913B (zh) 2012-07-04
ATE304866T1 (de) 2005-10-15
MXPA04000210A (es) 2004-07-23
GB0116815D0 (en) 2001-08-29
ES2250671T3 (es) 2006-04-16

Similar Documents

Publication Publication Date Title
US8852550B2 (en) Chelator conjugates
AU725827B2 (en) Radiometal-binding peptide analogues
US20100240072A1 (en) Cancer Imaging and Treatment
JP6164556B2 (ja) 非特異的腎集積が低減された放射性標識ポリペプチド作製用薬剤
AU2002317317A1 (en) Improved chelator conjugates
CA3207132A1 (en) Dual mode radiotracer and -therapeutics
CN117042812A (zh) 用于诊断和治疗用途的cxcr4-配体及其前体
JP5557425B2 (ja) 改良ｎ４キレーターコンジュゲート
CA2613439A1 (en) Hydrazide conjugates as imaging agents
US20130189186A1 (en) Apoptosis imaging agents based on lantibiotic peptides
WO2006094725A1 (en) Chelators for radioactively labeled conjugates comprising a stabilizing sidechain
KR20250016195A (ko) 전립선-특이적 막 항원(psma) 리간드
US8454936B2 (en) Metal chelators and methods of their use
JP2024120295A (ja) 放射性同位元素含有化合物、及びそれを含む骨用医薬
JP2025525111A (ja) 放射性医薬品のためのケイ素系フッ化物アクセプター基
HK40111230A (en) Cleavable radioligands for targeting cell surface receptors and uses thereof
HK1064585B (en) Improved chelator conjugates
AU2024298898A1 (en) Peptide structure targeting carbonic dehydrogenase ix and use thereof
MXPA06002312A (en) Compounds containing matrix metalloproteinase substrates and methods of their use

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20140711